Literature DB >> 10502721

Aberrant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma In situ of the breast.

E C Mommers1, A M Leonhart, S von Mensdorff-Pouilly, D J Schol, J Hilgers, C J Meijer, J P Baak, P J van Diest.   

Abstract

MUC1 mucin is a high molecular weight transmembrane glycoprotein expressed on the apical cell surface of normal glandular epithelia. In many human adenocarcinomas, this protein is up-regulated and/or underglycosylated, and its expression changes from apical to the entire cell membrane. It is thought that entire cell membrane expression of MUC1 reduces cell-cell and cell-extracellular matrix interactions and therefore may facilitate invasive growth and development of metastases. In this study, we determined immunohistochemically the expression of normal and underglycosylated MUC1 in normal breast tissue (n = 8) and in a spectrum of breast lesions, including usual ductal hyperplasia (n = 23), atypical ductal hyperplasia (n = 7), and ductal carcinoma in situ (DCIS) (n = 22). We used 4 monoclonal antibodies; 115D8 is directed to a glycopeptide, the other 3 to the peptide core of the molecule, of which 139H2 is not affected by the degree of glycosylation of MUC1, whereas SM3 and VU-4-H5 stain only underglycosylated forms. All cases showed apical positivity for 115D8 and 139H2. Entire cell membrane expression of fully (normal) glycosylated MUC1 was mainly found in DCIS lesions. Apical staining of SM3 was found in 38% of normal cases and 60% of the ductal lesions with no difference between the different subgroups. Apical staining of VU-4-H5 was found more often in DCIS (27%) than in normal tissue or ductal hyperplasia (3%). Membrane expression of underglycosylated MUC1 was found only in poorly differentiated DCIS. In conclusion, aberrant expression of MUC1, i.e., on the entire cell membrane and/or underglycosylated forms, can be found in ductal hyperplasia with atypia and especially in DCIS of the breast. This finding implies that these lesions with aberrant expression are at higher risk for developing subsequent invasive breast carcinoma. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502721     DOI: 10.1002/(sici)1097-0215(19991022)84:5<466::aid-ijc3>3.0.co;2-#

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Immunohistochemical study of the expression of MUC5AC and MUC6 in breast carcinomas and adjacent breast tissues.

Authors:  M B Pereira; A J Dias; C A Reis; F C Schmitt
Journal:  J Clin Pathol       Date:  2001-03       Impact factor: 3.411

2.  Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.

Authors:  Subrata K Ghosh; Masashi Uchida; Byunghee Yoo; Alana W Ross; Sandra J Gendler; Jianlin Gong; Anna Moore; Zdravka Medarova
Journal:  Int J Cancer       Date:  2012-10-25       Impact factor: 7.396

Review 3.  Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Authors:  Jason Lohmueller; Olivera J Finn
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

4.  Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.

Authors:  Pawel Ciborowski; Olivera J Finn
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

5.  Labeling of anti-MUC-1 binding single chain Fv fragments to surface modified upconversion nanoparticles for an initial in vivo molecular imaging proof of principle approach.

Authors:  Anja Hischemöller; Claudia Walter; Volker Weiler; Helga Hummel; Theo Thepen; Michael Huhn; Stephan Barth; Werner Hoheisel; Karen Köhler; Diana Dimova-Landen; Christoph Bremer; Markus Haase; Jens Waldeck
Journal:  Int J Mol Sci       Date:  2012-03-29       Impact factor: 6.208

6.  Differential expression of MUC genes in endometrial and cervical tissues and tumors.

Authors:  Vidya Hebbar; Gautam Damera; Goverdhan P Sachdev
Journal:  BMC Cancer       Date:  2005-09-27       Impact factor: 4.430

7.  MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate.

Authors:  C F Qu; Y Li; Y J Song; S M A Rizvi; C Raja; D Zhang; J Samra; R Smith; A C Perkins; C Apostolidis; B J Allen
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

8.  Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.

Authors:  Whitney Barham; Lianyi Chen; Oleg Tikhomirov; Halina Onishko; Linda Gleaves; Thomas P Stricker; Timothy S Blackwell; Fiona E Yull
Journal:  BMC Cancer       Date:  2015-09-30       Impact factor: 4.430

9.  Three to Tango: MUC1 as a Ligand for Both E-Selectin and ICAM-1 in the Breast Cancer Metastatic Cascade.

Authors:  Yue Geng; Kimberly Yeh; Tait Takatani; Michael R King
Journal:  Front Oncol       Date:  2012-07-27       Impact factor: 6.244

10.  Natural and Induced Humoral Responses to MUC1.

Authors:  Silvia Von Mensdorff-Pouilly; Maria Moreno; René H M Verheijen
Journal:  Cancers (Basel)       Date:  2011-07-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.